What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

14 February 2022

New publication “Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders”

In PRIME, we hypothesized that there might be shared underlying biological mechanisms between insulin-related somatic disorders and brain-based disorders. In this manuscript, coming out of the genetics work package of PRIME, we indeed show that there is a significant genetic overlap between somatic insulin-related disorders and brain-based disorders. This work is a proof-of-principle that we are on the right track in PRIME, where we will now continue to investigate which genetic variants play a role in this genetic overlap.

Read the full publication here.

To explore more PRIME publications, click here.

More News